左卡尼汀联合促红细胞生成素治疗尿毒症患者肾性贫血的临床疗效观察

Clinical effects of L-carnitine combined erythropoietin in uremic patients with renal anemia

目的观察左卡尼汀联合促红细胞生成素(rHu EPO)治疗尿毒症患者肾性贫血的疗效。方法将56例血液透析合并肾性贫血患者随机分成2组,两组均同时给予EPO,治疗组于每次透析结束后注射左卡尼汀,对照组不用左卡尼汀,治疗前和治疗中每个月复查血红蛋白(Hb)、红细胞压积(Hct),同时观察并发症的发生率,治疗12w后比较两组患者贫血纠正情况以及EPO用量。结果治疗12w后,两组Hb、Hct水平较治疗前明显升高(P<0.05～0.01),治疗组较对照组效果更显著,且EPO用量更少,差异有统计学意义(P<0.05～0.01)。结论左卡尼汀联合促红细胞生成素治疗肾性贫血可更明显地提高血红蛋白、红细胞压积水平,减少EPO的用量及其不良反应,提高了治疗肾性贫血的疗效。

Objective To observe the clinical effect of L-carnitine combined erythropoietin（rHu EPO） in treatment of renal anemia.Methods Fifty six of hemodialysis patients with renal anemia were randomly divided into two groups.Both two groups were treated with rHu EPO,while the case group were injected with L-carnitine,patients in the control group were not injected with L-carnitine.Month review before treatment and hemoglobin（Hb）,hematocrit（Hct） were observed before and during treatment,observed the incidence of complications,anemia correcting situation and the EPO dosage of 12 w were compared in patients of two groups.Results After 12 weeks of treatment,the Hb and Hct in both groups were hiher than that before treatment（P0.05~0.01）.The clinical effects in the case group was better than that in the control group,while the dosage of rHu EPO and the complication incidence in the case group was lower than that in the control group,and the difference was statistically significant（P0.05~0.01）.Conclusion L-carnitine combined erythropoietin treatment of renal anemia may be more significant increase of hemoglobin and hematocrit levels,reduce the amount of rHu EPO and its adverse effects,improved the effect of treatment of renal anemia.